Cerevance Media Center

Current News

July 21, 2020

Cerevance Expands Series B Financing to $65 Million

Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April.

READ FULL

April 14, 2020

Cerevance Closes $45 Million Series B Financing

Cerevance has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors...

READ FULL

January 7, 2020

Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors

Dr. Brennan is currently president and chief executive officer of Synlogic, Inc. (Nasdaq:SYBX), a clinical stage biotechnology company applying synthetic biology to beneficial microbes to develop novel, living medicines.

READ FULL

December 17, 2019

Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders

Cerevance has formed a multi-year research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain GI disorders.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

November 7, 2023

Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting

Date:
Wednesday, November 15, 2023
Time:
8am – 12pm ET
Location:
Washington, DC
Media:
Poster
Read full

November 1, 2023

Cerevance to Participate in the Truist Securities BioPharma Symposium

Date:
Thursday, November 9, 2023
Time:
9:50 – 10:35am ET
Location:
New York, NY
Media:
Panel Discussion
Read full

October 25, 2023

Cerevance to Participate at the Wells Fargo 2023 Private Biotech Symposium

Date:
Wednesday, November 1, 2023
Time:
Check for open times
Location:
Virtual
Media:
Scheduled Meetings
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

October 21, 2024

CVN424, a GPR6 Inverse Agonist, for Parkinson’s Disease and Motor Fluctuations: A Double-Blind, Randomized, Phase 2 Trial

Brice, Nicola L., Carlton, Mark, Margolin, David H., Bexon, Martin, Matthews, Kim L., Dawson, Lee A., Ellenbogen, Aaron L., Olanow, Warren C., Dubow, Jordan, and Kieburtz, Karl

Viewview

April 30, 2022

A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson’s Disease

Margolin, D.H., Brice, N.L., Davidson, A.M., Matthews, K.L., Carlton, M.B.L.

Viewview

June 30, 2021

Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease

Brice, N.L., Schiffer, H.H., Monenschein, H., Mulligan, V.J., Page, K., Powell, J., Xu, X., Cheung, T., Burley, J.R., Sun, H., Dickson, L., Murphy, S.T., Kaushal, N., Sheardown, S., Lawrence, J., Chen, Y., Bartkowski, D., Kanta, A., Hosea, N., Dawson, L.A., Hitchcock, S.H., Carlton, M.B.

Viewview

March 1, 2024

Discovery and First-time Disclosure of CVN766, an Exquisitely Selective Orexin 1 Receptor Antagonist

Glen, A., Bürli, R.W., Livermore, D., Buffham, W., Merison, S., Rowland, A.E., Newman, R., Fieldhouse, C., Miller, D.J., Dawson, L.A., Matthews, K., Carlton, M.B., Brice, N.L.

Viewview

April 5, 2024

Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment

Bürli, R. W., Doyle,K. J., Dickson, L., Rowland, A., Matthews, K., Stott, A. J., Teall, M., Ossola, B., Russell, S. G., Harvey, J. R. M., Wu,Y., Narayana, L., Brice, N. L., Carlton, M., Dawson, L. A.

Viewview

February 15, 2023

Characterisation of C101248: A Novel Selective THIK-1 Channel Inhibitor for the Modulation of Microglial NLRP3-Inflammasome

Ossola, B., Rifat, A., Rowland, A., Hunter, H., Drinkall, S., Bender, C., Hamlischer, M., Teall, M., Burley, R., Barke, D., Cadwalladr, D., Dickson, L., Lawrence, J., Harvey, J., Lizio, M., Xu, X., Kavanagh, E., Cheung, T., Sheardown, S., Lawrence, C.B., Harte, M., Brough, D., Madry, C., Matthews, K., Doyle, K., Page, K., Powell, J., Brice, N.L., Bürli, R.W., Carlton, M.B., Dawson L.A.

Viewview